JP2008538183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538183A5 JP2008538183A5 JP2008504533A JP2008504533A JP2008538183A5 JP 2008538183 A5 JP2008538183 A5 JP 2008538183A5 JP 2008504533 A JP2008504533 A JP 2008504533A JP 2008504533 A JP2008504533 A JP 2008504533A JP 2008538183 A5 JP2008538183 A5 JP 2008538183A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- seq
- antibody
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010027202 Meningitis bacterial Diseases 0.000 claims 2
- 201000009904 bacterial meningitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66792105P | 2005-03-30 | 2005-03-30 | |
| PCT/US2006/012606 WO2006110413A2 (en) | 2005-03-30 | 2006-03-30 | Haemophilus influenzae type b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538183A JP2008538183A (ja) | 2008-10-16 |
| JP2008538183A5 true JP2008538183A5 (enExample) | 2009-05-14 |
Family
ID=37087506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504533A Pending JP2008538183A (ja) | 2005-03-30 | 2006-03-30 | Ｂ型インフルエンザ菌 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20100034822A1 (enExample) |
| EP (1) | EP1871888A4 (enExample) |
| JP (1) | JP2008538183A (enExample) |
| CN (1) | CN101687025A (enExample) |
| AU (1) | AU2006235045A1 (enExample) |
| BR (1) | BRPI0609460A2 (enExample) |
| CA (1) | CA2602665A1 (enExample) |
| MX (1) | MX2007012057A (enExample) |
| NZ (2) | NZ591415A (enExample) |
| RU (1) | RU2007139915A (enExample) |
| WO (1) | WO2006110413A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| US11291635B2 (en) | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| TR201908635T4 (tr) | 2010-08-31 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler. |
| WO2012031043A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| JP2014516028A (ja) * | 2011-05-11 | 2014-07-07 | リースベック ヘルスケア スウェーデン アクティエボラーグ | ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子 |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP4014966A1 (en) | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| SG11201400250UA (en) | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| AR090303A1 (es) * | 2013-03-11 | 2014-11-05 | Consejo Nac Invest Cient Tec | Polipeptido mutado, cepa de bacterias que lo comprende y metodos para detectar diferentes cationes metalicos simultaneamente |
| US9868777B2 (en) | 2013-06-10 | 2018-01-16 | Merck Sharp & Dohme Corp. | CMV neutralizing antigen binding proteins |
| PT3083556T (pt) | 2013-12-19 | 2020-03-05 | Novartis Ag | Lípidos e composições lipídicas para a entrega de agentes ativos |
| WO2015095346A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| CN107072946B (zh) | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | 用于递送活性剂的脂质和脂质组合物 |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201508860D0 (en) | 2015-05-22 | 2015-07-01 | Nat Univ Ireland | Diagnostic method |
| US11401520B2 (en) | 2016-10-21 | 2022-08-02 | The Research Foundation For The State University Of New York | Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| EP3931206A1 (en) * | 2019-02-27 | 2022-01-05 | Evaxion Biotech ApS | Vaccines targeting h. influenzae |
| WO2020243697A1 (en) * | 2019-05-31 | 2020-12-03 | Rhogen Biotech Llc | Compositions and methods for detoxifying bacterial endotoxins |
| US11357845B2 (en) * | 2019-07-08 | 2022-06-14 | The Trustees Of The University Of Pennsylvania | Protein antigens for vaccinating against nontypeable Haemophilus influenzae |
| KR20230118715A (ko) | 2020-10-14 | 2023-08-11 | 조지 메이슨 리서치 파운데이션 인코포레이티드 | 이온화 가능 지질 및 이의 제조 및 사용 방법 |
| AU2021372524A1 (en) * | 2020-10-30 | 2023-05-04 | Gen-Probe Incorporated | Compositions and methods for detecting influenza a, influenza b, and sars-cov-2 |
| EP4387597A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
| US20260124157A1 (en) | 2024-08-09 | 2026-05-07 | Genvax Technologies, Inc. | Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355450B1 (en) * | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
| GB9513074D0 (en) * | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
| US6593114B1 (en) * | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| US6914131B1 (en) * | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| US6730827B1 (en) * | 1998-07-14 | 2004-05-04 | E. I. Du Pont De Nemours And Company | Genes encoding plant adenosine 5′-phosphosulfate reductase |
| US7365185B2 (en) * | 2000-07-19 | 2008-04-29 | Monsanto Technology Llc | Genomic plant sequences and uses thereof |
| KR20020097200A (ko) * | 2000-03-21 | 2002-12-31 | 엘리트라 파마슈티컬즈, 인코포레이티드 | 원핵세포에서의 필수유전자의 동정 |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US7192923B2 (en) * | 2002-01-16 | 2007-03-20 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| CA2517899A1 (en) * | 2003-03-06 | 2004-09-16 | Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| GB0315022D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Virulence-associated adhesins |
| GB0410866D0 (en) * | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| JP2008546390A (ja) * | 2005-06-16 | 2008-12-25 | ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド | 分類不能型インフルエンザ菌の中耳炎単離物の遺伝子 |
-
2006
- 2006-03-30 CA CA002602665A patent/CA2602665A1/en not_active Abandoned
- 2006-03-30 AU AU2006235045A patent/AU2006235045A1/en not_active Abandoned
- 2006-03-30 MX MX2007012057A patent/MX2007012057A/es unknown
- 2006-03-30 NZ NZ591415A patent/NZ591415A/xx not_active IP Right Cessation
- 2006-03-30 JP JP2008504533A patent/JP2008538183A/ja active Pending
- 2006-03-30 US US11/887,712 patent/US20100034822A1/en not_active Abandoned
- 2006-03-30 NZ NZ562381A patent/NZ562381A/en not_active IP Right Cessation
- 2006-03-30 EP EP06758272.6A patent/EP1871888A4/en not_active Withdrawn
- 2006-03-30 BR BRPI0609460-0A patent/BRPI0609460A2/pt not_active IP Right Cessation
- 2006-03-30 CN CN200680018203A patent/CN101687025A/zh active Pending
- 2006-03-30 WO PCT/US2006/012606 patent/WO2006110413A2/en not_active Ceased
- 2006-03-30 RU RU2007139915/13A patent/RU2007139915A/ru not_active Application Discontinuation
-
2011
- 2011-12-21 US US13/333,815 patent/US20120093868A1/en not_active Abandoned
-
2014
- 2014-06-19 US US14/309,829 patent/US20140302078A1/en not_active Abandoned
-
2015
- 2015-10-06 US US14/876,623 patent/US20160024157A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525033A5 (enExample) | ||
| RU2007139915A (ru) | Haemophilus influenzae типа в | |
| JP2010166916A5 (enExample) | ||
| JP2012000112A5 (enExample) | ||
| RU2006144093A (ru) | Полипептиды нетипируемой haemophilus influenzae | |
| JP2003527079A5 (enExample) | ||
| JP2011004753A5 (enExample) | ||
| JP2008508859A5 (enExample) | ||
| JP2010273685A5 (enExample) | ||
| RU2009102815A (ru) | Полипептиды из neisseria meningitidis | |
| JP2006516189A5 (enExample) | ||
| JP2005511076A5 (enExample) | ||
| JP2015514132A5 (enExample) | ||
| JP2004511201A5 (enExample) | ||
| JP2002531129A5 (enExample) | ||
| JP2007502101A5 (enExample) | ||
| JP2012515557A5 (enExample) | ||
| JP2012522010A5 (enExample) | ||
| JP2002542827A5 (enExample) | ||
| JP2017507181A5 (enExample) | ||
| EP2292644A3 (en) | Small Streptococcus pyogenes antigens and their use | |
| JP2012505657A5 (enExample) | ||
| JP2019534884A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections |